Hospitalization Burden and Outcomes in Congenital Adrenal Hyperplasia Across the Lifespan: Insights from a Swiss Population-Based Cohort Study

Hospitalization Burden and Outcomes in Congenital Adrenal Hyperplasia Across the Lifespan: Insights from a Swiss Population-Based Cohort Study

This study reveals that individuals with Congenital Adrenal Hyperplasia (CAH) experience early, frequent, and complex hospitalizations with higher risk of severe outcomes, especially in infancy, compared to non-CAH patients, emphasizing the need for age-specific care strategies.
Understanding Acute Hypoxemic Respiratory Failure in ICU Patients: Epidemiology, Ventilatory Management, and Outcomes from a Multi-ICU Cohort Study

Understanding Acute Hypoxemic Respiratory Failure in ICU Patients: Epidemiology, Ventilatory Management, and Outcomes from a Multi-ICU Cohort Study

This study reveals that acute hypoxemic respiratory failure (AHRF) affects half of ICU patients needing respiratory support, with severity linked to worse outcomes. Lung-protective ventilation is common, underscoring the need for standardized AHRF definitions to guide treatment and research.
Secondary Autoimmune and Inflammatory Diseases Post-Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, and Clinical Outcomes from the EBMT Registry

Secondary Autoimmune and Inflammatory Diseases Post-Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Risk Factors, and Clinical Outcomes from the EBMT Registry

This retrospective EBMT study identifies secondary autoimmune and inflammatory diseases as rare but significant complications following allo-HSCT, highlighting their incidence, risk factors, and impact on patient survival, calling for improved diagnostic and management strategies.
Rising Tide of Primary Hyperparathyroidism: Stockholm Study Reveals Dramatic Increase in Incidence and Prevalence Over 15 Years

Rising Tide of Primary Hyperparathyroidism: Stockholm Study Reveals Dramatic Increase in Incidence and Prevalence Over 15 Years

A landmark population-based study spanning 2006-2020 in Stockholm, Sweden, reveals that biochemically confirmed primary hyperparathyroidism incidence increased by 52% while only half of affected patients received clinical diagnosis, highlighting significant diagnostic gaps in this treatable endocrine disorder.